Brief: EyePoint announces positive recommendation by Data Safety Monitoring Committee for phase 3 trials for Duravyu
19/11/2025 12:17
Nov 19 (Reuters) - EyePoint Pharmaceuticals Inc EYPT.O: EYEPOINT ANNOUNCES POSITIVE RECOMMENDATION FROM INDEPENDENT DATA SAFETY MONITORING COMMITTEE FOR PIVOTAL PHASE 3 TRIALS FOR DURAVYU™ IN WET AGE-RELATED MACULAR DEGENERATION EYEPOINT PHARMACEUTICALS INC - TOPLINE DATA FOR LUGANO EXPECTED MID-2026 Source text: nGNX9n2Gk7 Further company coverage: EYPT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on EyePoint
See all newsUS RESEARCH ROUNDUP-Axon Enterprise, Williams-Sonoma, Xcel Energy
US STOCKS ON THE MOVE-CoreWeave, Moderna, Datadog
U.S. STOCKS ON THE MOVE-Amazon, CoreWeave, Moderna
U.S. STOCKS ON THE MOVE-Centrus Energy, Disc Medicine, Crypto
EyePoint to halve workforce after experimental drug fails second late-stage trial (updated)